During a randomized controlled trial of interferon and descyclovir therapy, the β 2-microglobulin and SGOT serum levels in 36 patients with chronic HBe-positive hepatitis B were studied in order to determine whether β 2-microglobulin has prognostic value for HBe seroconversion. Pretreatment levels of β 2-microglobulin were elevated in 39% of patients. Significant differences in mean β 2-microglobulin activity and mean SGOT between treated patients and untreated controls were observed after 4 and 8 weeks of treatment ( P<0.05). Levels in control patients remained stable. Prior to and during therapy, the mean elevation of β 2-microglobulin and SGOT levels was similar in responders ( N=7) and non-responders ( N=11). The outcome of antiviral therapy in our patients was not dependent on β 2-microglobulin levels measured before or during interferon therapy.